| Cardiovascular Regenerative Medicine: The Developing Heart Meets Adult Heart Repair.
November 21, 2009 at 6:51 am
|
| | Cardiovascular Regenerative Medicine: The Developing Heart Meets Adult Heart Repair. Circ Res. 2009 Nov 20;105(11):1041-1043 Authors: PMID: 19926879 [PubMed - as supplied by publisher] |
| Efficacy of Bone Marrow-derived Mesenchymal Stem Cells in the Treatment for Sclerodermatous Chronic Graft-versus-Host Disease: A clinical report of four patients.
November 21, 2009 at 6:51 am
|
| | Efficacy of Bone Marrow-derived Mesenchymal Stem Cells in the Treatment for Sclerodermatous Chronic Graft-versus-Host Disease: A clinical report of four patients. Biol Blood Marrow Transplant. 2009 Nov 16; Authors: Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y, Ai H, Zhao RC The treatment for sclerodermatous chronic graft-versus-host disease (ScGVHD) remains disappointing. The immunomodulatory ability of bone marrow-derived mesenchymal stem cells (MSCs) gives it a promising future to apply the cells to GVHD, especially with previous success in treating patients with acute GVHD. There remains much, however, for the potential efficacy and safety issues for chronic GVHD (cGVHD), particularly ScGVHD patients, to be clarified. Here we report 4 patients with ScGVHD who received MSCs expanded ex vivo from unrelated donors by intrabone marrow injection (IBMI). After MSCs infusion, the ratio of helper T lymphocyte (Th) 1 to Th2 was dramatically overturned, with an increase of Th1 and a decrease of Th2 reaching at a new balance. Correspondingly, symptoms of all the four patients gradually improved. During the course of MSCs treatment, the life signs and laboratory results from the recipients remained normal. By the time of this report, there has been no recurrence of leukemia in the four patients. In conclusion, although this study alone cannot guarantee the application of MSCs in ScGVHD, the results are strongly in favor of the idea that the MSCs treatment for ScGVHD patients is therapeutically practical without any detectable side effects, which may provide a new insight into the matter of treating ScGVHD clinically, thus will greatly increase the survival rate of leukemia after allogeneic bone marrow transplantation. PMID: 19925878 [PubMed - as supplied by publisher] |
| Immunofluorescence microscopy for imaging of nuclear p63 in human primary keratinocytes: A comparison of antibodies and fixation methods.
November 21, 2009 at 6:51 am
|
| | Immunofluorescence microscopy for imaging of nuclear p63 in human primary keratinocytes: A comparison of antibodies and fixation methods. J Immunol Methods. 2009 Nov 16; Authors: Markert CD, Bharadwaj S, Zhang Y, Childers MK, Furth ME The ability of an experimental treatment to induce primitive, undifferentiated stem cells towards an epidermal fate may be tested by comparing the treated stem cells with a positive control, such as primary keratinocytes. In an effort to perfect methods used for this comparison, we tested two commercially available antibodies and three fixation methods to determine which antibody/fixation interaction produced the best immunofluorescent images of the nuclear localization of p63, a canonical marker of epidermal fate, in keratinocytes. Here, we report the methods used, and the experimental outcome. PMID: 19925805 [PubMed - as supplied by publisher] |
| TNNI3K Could be a Novel Molecular Target for the Treatment of Cardiac Diseases.
November 21, 2009 at 6:51 am
|
| | TNNI3K Could be a Novel Molecular Target for the Treatment of Cardiac Diseases. Recent Pat Cardiovasc Drug Discov. 2009 Nov;4(2):203-210 Authors: Lai ZF Recently, regenerative medicine using the transplantation of embryonic stem cells and bone marrow stem cells has been a great success but still has many unconfirmed problems including its clinical evaluation. The aim of this article is to review current literature and some patents regarding molecular therapeutic agents including using MAP kinase TNNI3K for the treatment and diagnosis of acute myocardial ischemia or infarction. TNNI3K is a novel cardiac troponin I-interacting kinase gene and its overexpression may promote cardiac myogenesis, improve cardiac performance, and attenuate ischemia-induced ventricular remodeling. The modulation of embryonal stem cells with high TNNI3K activity using a TNNI3K active peptide could be a useful therapeutic approach for ischemic cardiac diseases. For overexpressing TNNI3K or enhancing TNNI3K activity in cardiac precursor cells, the engraftment of bone marrow cells or embryonic stem cells can effectively promote cardiac myogenesis, beating frequency, and contractile functions, and decrease "silent" (no contraction) cardiac cells after cell transplantion, indicating that the overexpression of TNNI3K can increase the success rate of transplanting embryonic stem cells or bone marrow cells into ischemic hearts for the treatment of ischemic cardiac diseases. Although previous investigations showing that TNNI3K may be involved in the development of cardiac hypertrophy, it is still unclear whether TNNI3K has a role in cardiac hypertrophy or what mechanism is involved in the effects of TNNI3K. To confirm this, further investigations need to be undertaken. PMID: 19925440 [PubMed - as supplied by publisher] |
| Long Bone Defect Models for Tissue Engineering Applications: Criteria for Choice.
November 21, 2009 at 6:51 am
|
| | Long Bone Defect Models for Tissue Engineering Applications: Criteria for Choice. Tissue Eng Part B Rev. 2009 Nov 19; Authors: Horner EA, Kirkham J, Wood D, Curran SJ, Smith M, Thomson B, Yang XB The replacement and repair of bone lost due to trauma, cancer or congenital defects is a major clinical challenge. Skeletal tissue engineering is a potentially powerful strategy in modern regenerative medicine and research in this field has increased greatly in recent years. Tissue engineering strategies seek to translate research findings in the fields of materials science, stem cell biology and biomineralisation into clinical applications, demanding the use of appropriate in vivo models to investigate bone regeneration of the appendicular axislong bone. However, identification of the optimal in vivo segmental bone defect model from the literature is difficult due to the use of different animal species (large and small mammals), different bones (weight-bearing and non-weight bearing) and multiple protocols, including the use of various scaffolds, cells and bioactives. The aim of this review is to summarize the available animal models for evaluating appendicularlong bone regeneration in vivo. We highlight the differences not only in species and sites but also in defect size, means of defect creation, duration of study and fixation method. A critical evaluation of the most clinically-relevant models is addressed to guide the researcher in his/her choice of the most appropriate model to use in future hypothesis-driven investigations. PMID: 19925211 [PubMed - as supplied by publisher] |
| Repair of Canine Mandibular Bone Defects with Bone Marrow Stromal Cells and Coral.
November 21, 2009 at 6:51 am
|
| | Repair of Canine Mandibular Bone Defects with Bone Marrow Stromal Cells and Coral. Tissue Eng Part A. 2009 Nov 19; Authors: Yuan J, Zhang W, Liu G, Wei M, Qi Z, Liu W, Cui L, Cao Y Tissue engineering has become a new approach for repairing bone defects. Previous studies indicated coral scaffolds have been utilized with bone marrow stromal cells (BMSCs) in a variety of approaches for bony reconstruction. In these applications, the degradation rate of the material did not match the rate at which bone was regenerated. In this study, a previously established 30 mm long mandibular segmental defect was repaired with engineered bone using GFP-labeled osteogenic BMSCs seeded on porous coral (n=12). Defects treated with coral alone (n=12) were used as an experimental control. In the BMSCs/coral group, new bone formation was observed from 4 weeks post-operation, and bony-union was achieved after 32 post-operative weeks. The residual coral volume of the BMSCs/coral grafts at 12 weeks (20~30%) was significantly higher than that at 32 weeks (10~15%p < 0.05), which was detected by Micro-CT and histological examination. The engineered bone with BMSCs/coral achieved a satisfactory biomechanical properties at 32 weeks post-operation, which was very close to that of the contralateral edentulous mandible. More importantly, immunostaining demonstrated that the implanted BMSCs differentiated into osteoblast-like cells. In contrast, minimal bone formation with almost solely fibrous connection was observed in the group treated with coral alone. Based on these results, we conclude that engineered bone from osteogenically induced BMSCs and biodegradable coral can successfully repair the critical-sized segmental mandibular defects in canines and the seeding cells could be used for bony restoration. PMID: 19925049 [PubMed - as supplied by publisher] | | | 
|
No comments:
Post a Comment